Fig. 2From: Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissectionBiochemical recurrence-free survival in patients after salvage ePLND (n = 45) comparing patients with (n = 10) and without (n = 35) bone metastasesBack to article page